This author has not written his bio yet.
But we are proud to say that Etira contributed 37 entries already.
Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled “A Phase 1 Trial of ERX-315 in Participants with Advanced Solid Tumors” The trial will begin […]
Melbourne, Australia – July 10, 2024: The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities for innovation across medicine formulation, resolving manufacturing process challenges and building supply of highly-skilled, industry ready candidates for the workforce. MMIC […]
Dallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions. Herein, the design of oligo-benzamides, efficient synthetic routes and preclinical studies showing their activity are detailed. Etira’s therapeutic compounds are based on […]
Dallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This submission marks a significant milestone for EtiraRx and approval by HREC will enable the start of phase 1 […]
San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity is dependent on LIPA expression. The data support the advancement of ERX-208 towards clinical trials in ovarian cancer. […]
Dallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes of ovarian cancer- serous carcinoma, mucinous carcinoma, endometrioid adenocarcinoma and clear cell carcinoma. These […]
San Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms of endocrine therapy resistant breast cancer, including those driven by mutant estrogen receptor. Preclinical research, GMP […]
Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany. The authors conclude that LIPA-activity is a novel pharmacological target in TNBC therapy and argue for the implementation of LIPA inhibitors into personalized treatment […]
Dallas, Texas. June 1, 2023: One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress” has the highest almetric score for any paper published in Nature Cancer. […]
Dallas, Texas. April 18, 2023: Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented at The American Association for Cancer Research (AACR) annual meeting, demonstrate strong efficacy in multiple preclinical models both in vitro and […]
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247